CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Allakos (ALLK) plunges 88% after poor clinical trial results

By Robert Davis

17:30, 22 December 2021

A scientist holds a laboratory test tube and does a test of biological material for DNA
Over the past year, Allakos has seen its stock price fall by more than 92% Credit: Shutterstock

The stock of American biotech company Allakos (ALLK) plunged 88% to $9.61 on Wednesday after the company reported statistically insignificant results from the clinical trial of a new drug.

Over the past year, the company has seen its stock price fall by more than 92% – a $124 drop.

According to the Phase 3 test results, Allakos’ drug lirentelimab did not achieve a meaningful reduction in symptoms for gastrointestinal patients after 24 weeks of use.


The study also found that 34% of lirentelimab-treated patients experienced mild to moderate infusion-related reactions such as flushing, headache and nausea.

The Redwood City, California-based company has been developing its drug since at least 2018 and began expanding its development to include other ailments like asthma and atopic dermatitis back in November.


1,993.83 Price
-0.460% 1D Chg, %
Long position overnight fee -0.0199%
Short position overnight fee 0.0117%
Overnight fee time 22:00 (UTC)
Spread 0.50


16,064.40 Price
-0.140% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8


42,291.50 Price
-3.690% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00


0.63 Price
-6.210% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Dr Robert Alexander, Allakos’ chief executive, said he was “deeply disappointed” in the test results, while chief medical officer Dr Craig Paterson said the company plans to continue expanding its development efforts next year.

Price downgrade

Analysts at William Blair downgraded Allakos to ‘market perform’ on Wednesday following the test results.

“While we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient-reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements,” said Tim Lugo, a William Blair analyst, in a note to investors.

Despite the test results, Lugo added that there was still a viable space for lirentelimab in the market but he wants to see how the drug responds in other treatment plans before revisiting Allakos’ rating.

Read more: Outperforming biotech stocks you should keep an eye on

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading